IIT Kanpur Researchers Solve Mystery of Atypical Drug Target Receptor

Researchers at the Indian Institute of Technology (IIT) Kanpur have finally cracked the long-standing mystery behind the atypical behavior of C5aR2, a crucial immune receptor, a discovery set to revolutionize drug design. Led by Professor Arun K Shukla, the team used advanced Cryo-electron microscopy (cryo-EM) to map the receptor's molecular structure, revealing why it acts differently from its close counterpart, C5aR1. This breakthrough moves us closer to developing highly targeted medicines with fewer side effects. For years, C5aR2 has been a puzzle for scientists because, despite its structural similarity to C5aR1 on the outside, its internal workings follow unique Signaling pathways, playing a critical role in the body's Complement system—our first line of defense against infections. Understanding this functional divergence is key, as both receptors are involved in regulating Inflammation and immune responses, making C5aR2 an important, albeit elusive, target for various diseases. The powerful visualization capabilities of cryo-EM were instrumental in finally unveiling these atomic-level details. The IIT Kanpur team didn't just stop at understanding the mystery; they also developed a new Selective molecule called R8Y, which specifically targets C5aR2 without affecting C5aR1. This precision is a game-changer for Drug design, promising future therapies that can more accurately modulate immune responses. The next crucial step involves testing R8Y in Animal models, paving the way for safer and more effective treatments for inflammatory and autoimmune conditions.